cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Crinetics Pharmaceuticals Inc
2 own
3 watching
Current Price
$19.92
$-0.2
(-0.99%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,071.62M
52-Week High
52-Week High
27.86
52-Week Low
52-Week Low
15.37
Average Volume
Average Volume
0.27M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,071.62M
icon52-Week High27.86
icon52-Week Low15.37
iconAverage Volume0.27M
iconDividend Yield--
iconP/E Ratio--
What does the Crinetics Pharmaceuticals Inc do?
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing s and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Read More
How much money does Crinetics Pharmaceuticals Inc make?
News & Events about Crinetics Pharmaceuticals Inc.
Globe Newswire
26days ago
Efforts to further increase commercial readiness ongoing as Phase 3 PATHFNDR trials of paltusotine in acromegaly approach topline data readouts which are expected in 2H 2023 Phase 2 trial of paltusotine in carcinoid syndrome on track for topline data in 2H 2023 Clinical trials of CRN04894 in ACTH-...
Globe Newswire
2 months ago
SAN DIEGO, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today provided an update on its development program for CRN04777, an investigational, oral somatostatin receptor type 5 (SST5) agonist being developed as a treatment for congenital hyperinsulinism (HI). On ...
Globe Newswire
2 months ago
SAN DIEGO, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc.(Nasdaq: CRNX), today announced that company management will participate in a fireside chat and 1x1 investor meetings at the 5th Annual Evercore ISI HealthCONx Conference being held virtually November 29 December 1, 2022. ...
Globe Newswire
5 months ago
SAN DIEGO, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX) today announced that Monica R. Gadelha, MD, PhD, professor of endocrinology at the Medical School of the Universidade Federal do Rio de Janeiro and a principal investigator in the Phase 2 ACROBAT program, will be ...
Globe Newswire
5 months ago
Paltusotines Phase 3 PATHFNDR Program in Acromegaly and Phase 2 Program in Carcinoid Syndrome Remain on Track for Top-Line Data in 2023 CRN04894 Phase 1 Data Demonstrated Pharmacologic Proof-of-Concept for Further Development in Both Cushings Disease and Congenital Adrenal Hyperplasia CRN04777 and ...
Frequently Asked Questions
Frequently Asked Questions
What is Crinetics Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Crinetics Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Crinetics Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Crinetics Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Crinetics Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Crinetics Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Crinetics Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Crinetics Pharmaceuticals Inc?
plus_minus_icon
What percentage is Crinetics Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Crinetics Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$19.92
$-0.2
(-0.99%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
INHIBRX INC
INHIBRX INC
$25.80
$0.72 (2.87 %)
ARCUTIS BIOTHERAPEUTICS INC
ARCUTIS BIOTHERAPEUTICS INC
$16.67
$0.32 (1.96 %)
Avid Bioservices Inc
Avid Bioservices Inc
$16.19
$-0.43 (-2.59 %)
Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals Ltd
$14.10
$-0.07 (-0.49 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
INHIBRX INC
INHIBRX INC
$25.80
$0.72 (2.87 %)
ARCUTIS BIOTHERAPEUTICS INC
ARCUTIS BIOTHERAPEUTICS INC
$16.67
$0.32 (1.96 %)
Avid Bioservices Inc
Avid Bioservices Inc
$16.19
$-0.43 (-2.59 %)
Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals Ltd
$14.10
$-0.07 (-0.49 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00